Literature DB >> 16646074

Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer.

Tobias Zellweger1, Gabriel Benz, Gieri Cathomas, Michael J Mihatsch, Tullio Sulser, Thomas C Gasser, Lukas Bubendorf.   

Abstract

The objective of this study was to evaluate the diagnostic value of chromosomal analysis by fluorescence in situ hybridization (FISH) for predicting recurrence of urothelial carcinoma (UC) after transurethral resection. One hundred and thirty-eight patients (median age 68.5 years) with a history of UC were eligible for this prospective study. FISH was applied to cytospin specimens prepared from bladder washings taken during a negative control cystoscopy. The multi-target FISH test UroVysion (Abbott/Vysis) containing probes to the centromeres of chromosomes 3, 7, 17 and the 9p21 locus was used. UC recurrence was defined as a positive biopsy during follow-up. The median follow-up time was 19.2 (4-52) months. FISH was positive in 50 (36%) patients and negative in 88 (64%) patients. A recurrence occurred in 39% of the patients with a positive FISH test and in 21% of patients with a negative FISH test. FISH positivity according to manufacturer's criteria, at the time of a negative cystoscopy, was not significantly associated with the risk of recurrence (p = 0.12). However, the sensitivity of the FISH test to predict recurrence was significantly improved by considering specimens with rare (< or =10) tetraploid cells as negative (p < 0.006). In addition, presence of 9p21 deletion was significantly associated with recurrence (p < 0.01). Notably, positive standard cytology was an independent factor for subsequent recurrence in this study (p < 0.001). Taken together, multi-target FISH may help to stratify the risk of recurrence of UC at the time of a negative follow-up cystoscopy. Defining the optimal threshold for FISH positivity requires consideration of tetraploid pattern and 9p21 deletion. Our results also emphasize the paramount importance of conventional cytology for UC surveillance. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16646074     DOI: 10.1002/ijc.21704

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  [Personalized urooncology based on molecular uropathology: part 1: what is diagnostic routine?].

Authors:  C G Stöhr; R Stöhr; A Rogler; K Amann; R Knüchel-Clarke; A Hartmann
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

2.  Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization.

Authors:  Johannes Mischinger; Lutz Philipp Guttenberg; Jörg Hennenlotter; Georgios Gakis; Stefan Aufderklamm; Steffen Rausch; Eva Neumann; Jens Bedke; Stefan Kruck; Christian Schwentner; Arnulf Stenzl; Tilman Todenhöfer
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-02       Impact factor: 4.553

3.  Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

Authors:  Ashish M Kamat; Rian J Dickstein; Fabrizio Messetti; Roosevelt Anderson; Shanna M Pretzsch; Graciela Noguera Gonzalez; Ruth L Katz; Abha Khanna; Tanweer Zaidi; Xifeng Wu; H Barton Grossman; Colin P Dinney
Journal:  J Urol       Date:  2012-01-15       Impact factor: 7.450

Review 4.  Biomarkers for bladder cancer management: present and future.

Authors:  Fei Ye; Li Wang; Mireia Castillo-Martin; Russell McBride; Matthew D Galsky; Jun Zhu; Paolo Boffetta; David Y Zhang; Carlos Cordon-Cardo
Journal:  Am J Clin Exp Urol       Date:  2014-04-05

Review 5.  Microfluidic sample preparation for diagnostic cytopathology.

Authors:  Albert J Mach; Oladunni B Adeyiga; Dino Di Carlo
Journal:  Lab Chip       Date:  2013-03-21       Impact factor: 6.799

6.  Chromosomal aneuploidies and combinational fluorescence in situ hybridization probe panels are useful for predicting prognosis for esophageal squamous cell carcinoma.

Authors:  Jia-Jie Hao; Han-Qing Yao; Guang-Yun Dai; Wei Kang; Xue-Mei Jia; Xin Xu; Yan Cai; Qi-Min Zhan; Gui-Qi Wang; Ming-Rong Wang
Journal:  J Gastroenterol       Date:  2014-05-11       Impact factor: 7.527

7.  Endoscopic transpapillary brush cytology and forceps biopsy in patients with hilar cholangiocarcinoma.

Authors:  Andreas Weber; Claus von Weyhern; Falko Fend; Jochen Schneider; Bruno Neu; Alexander Meining; Hans Weidenbach; Roland M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

8.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 9.  [Cytology of the urinary tract: Between uncertainty and clarity].

Authors:  L Bubendorf; P Dalquen; S Savic
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

10.  The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.

Authors:  Kyung Won Kwak; Sun Hee Kim; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.